Further maintenance of remission for a year after infliximab withdrawal in ulcerative colitis treatment: a multicenter, controlled trial in Japa
Not Applicable
- Conditions
- ulcerative colitis
- Registration Number
- JPRN-UMIN000012092
- Lead Sponsor
- Center for Clinical Research, Keio University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 250
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients who are maintained remission for longer than 16 weeks. 2) Patients who have relapsed after once induced remission but before registered to the study. 3) Females who are pregnant, breast-feeding, or cannot exclude the possibility of pregnancy. 4) Patients who have a history of severe infusion reaction. 5) Patients who are considered ineligible for this study by the principal investigator or collaborative doctors.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method remission rate after 48 weeks
- Secondary Outcome Measures
Name Time Method